Skip to main content
SpringerLink
Log in

Pharmaceutical Policies in Canada

Issues and Challenges

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Prescription and over-the-counter medications are an important and widely used part of healthcare in Canada. Such drugs represent an increasing proportion of total healthcare expenditures. The objectives of the paper are to examine pharmaceutical expenditures and utilisation in Canada, review the major cost control strategies for pharmaceuticals, and discuss the future issues and challenges for pharmaceutical policy in Canada. Compared with other Organisation for Economic Cooperation and Development (OECD) countries, Canada (until recently) has not been successful in controlling the rate of increase of healthcare expenditures and, more specifically, pharmaceutical costs. The key variables associated with high rates of increase in drug costs relate to increased per capita use of drugs, use of more expensive drugs, and rising prices of existing drugs. If policies are going to address the fundamental societal issues behind both the price and utilisation elements of pharmaceuticals, policy makers and third-party payers in Canada will probably have to focus, primarily, on manufacturers and major healthcare providers and, secondarily, on consumers. They will need to develop an internally valid package of consistent policies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Holbrook AM, McLeod SM, Fisher P, et al. Developing a Canadian Prescribing practices network. Can Med Assoc J 1996; 154(9): 1325–31

    CAS  Google Scholar 

  2. Health Canada. National health expenditures in Canada 1975- 1993. Ottawa: Supply and Services Canada, 1994

    Google Scholar 

  3. Kennedy W. Managing pharmaceutical expenditures: how Canada compares. Canada Health Action: building on the legacy. Vol 4. Striking a balance; health care systems in Canada and elsewhere. Ottawa: Health Canada, 1998

    Google Scholar 

  4. Auer L, Angus DE, Cloutier JE, et al. Cost-effectiveness of Canadian health care. Ottawa: Queens University of Ottawa Economic Projects, 1995

    Google Scholar 

  5. Morgan SG. Issues for Canadian Pharmaceutical Policy. Canada Health Action: building on the legacy. Vol 4. Striking a balance; health care systems in Canada and elsewhere. Ottawa: Health Canada, 1998

    Google Scholar 

  6. Gorecki P. Controlling drug expenditures in Canada: the Ontario experience. Ottawa: Economic Council of Canada, 1992

    Google Scholar 

  7. Lexchin J. Prescribing and drug costs in the province of Ontario. Int J Health Serv 1992; 22(3): 471–87

    Article  PubMed  CAS  Google Scholar 

  8. British Columbia Ministry of Health. Pharmacare initiatives saving money, improving services [press release]. Vancouver: Ramsay, 1995

    Google Scholar 

  9. Anderson GM, Lavis JN. Prescription drug use in the elderly: expenditures and patterns of use under Ontario and British Columbia provincial drug benefit programs. Ottawa: Queens University of Ottawa Economic Projects, 1994

    Google Scholar 

  10. Castonguay C, Borgeat L, Champigny-Robillard L, et al. Drug insurance: possible approaches. Report of the Committee of Experts on Drug Insurance (Bibliothèque nationale du Québec); 1996

    Google Scholar 

  11. Chiles V. Drug claims costs: a Green Shield Study. Can Pharm J 1995 Nov; 128(9): 39–43

    Google Scholar 

  12. Crop Conseil. Drug Benefit Programs in Canada. 1995

  13. Patented Medicine Prices Review Board. Eighth Annual Report: for the year ended December 31, 1995. Ottawa:TSupply and Services Canada, 1996

    Google Scholar 

  14. Patented Medicine Prices Review Board 1996. The top 200 selling patented drug products in Canada. Ottawa: Supply and Services Canada, 1994

    Google Scholar 

  15. Lexchin J. Canadian marketing codes: how well are they controlling pharmaceutical promotion? Int J Health Serv 1994; 24(1): 91–104

    Article  PubMed  CAS  Google Scholar 

  16. Drake D, Uhlman M. Making medicine, making money. Kansas Universal Press Syndicate, 1993

    Google Scholar 

  17. Eastman HC. Report of the commission of inquiry on the pharmaceutical industry. Ottawa: Supply and Services Canada, 1985

    Google Scholar 

  18. Rachlis M, Kushner C, editors. Unhealthy alliance: medicine and the drug industry. In: Strong medicine: how to save Canada’s health care system. Toronto: Harper Collins Publishers Ltd, 1994: 124–51

    Google Scholar 

  19. Lexchin J. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? Can Med Assoc J 1997; 156(3): 351–6

    CAS  Google Scholar 

  20. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. Can Med Assoc J 1994; 150: 1801–9

    CAS  Google Scholar 

  21. Manning PR, Lee PV, Clintworth WA, et al. Changing prescribing practices through individual continuing education. JAMA 1986; 256: 230–2

    Article  PubMed  CAS  Google Scholar 

  22. Pineault R. The effect of prepaid group practice on physicians utilisation behaviour. Med Care 1986; 14: 121

    Article  Google Scholar 

  23. Tamblyn R, Perreault R. Methods to encourage the sensible use of prescription medication in the elderly. Position paper for The National Health Forum. Ottawa: Health Canada, 1995

    Google Scholar 

  24. Decter MB. Healing medicare: managing health care system change the Canadian way. Toronto: McGilligan Books, 1994

    Google Scholar 

  25. Hurley J, Johnson N. The effects of co-payments within drug reimbursement programs. Canadian Public Policy 1991; 17(4): 473–89

    Article  Google Scholar 

  26. Reeder CE, Lingle EW, Schulz RM, et al. Economic impact of cost-containment strategies in third party programmes in the US. Pharmacoeconomics 1993; 4(2): 92–103

    Article  PubMed  CAS  Google Scholar 

  27. Evans RG, Williamson MF. Extending Canadian Health Insurance: options for Pharmacare and Denticare. Ontario Economic Council. Toronto: University of Toronto Press, 1978

    Google Scholar 

  28. Bacovsky RA. Drug submission, review, and approval processes for provincial and territorial government sponsored prescription drug plans in Canada. Report to the Joint Liaison Committee between the pharmaceutical industry and the Ontario government (mimeo). Toronto, 1997

    Google Scholar 

  29. Green Shield Canada. A report on drug costs. North York: Green Shield Canada, 1994

    Google Scholar 

  30. Reeder CE, Nelson Jr AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry. 1985; 22: 396–403

    PubMed  CAS  Google Scholar 

  31. Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid. N Engl J Med 1987; 317: 550–6

    Article  PubMed  CAS  Google Scholar 

  32. Soumerai SB, Ross-Degnan D, Fortess EE, et al. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Millbank Q 1993; 71(2): 217–52

    Article  CAS  Google Scholar 

  33. Levy RA. Prescription cost sharing: economic and health impacts and implications for health policy. Pharmacoeconomics 1992; 2: 219–37

    Article  PubMed  CAS  Google Scholar 

  34. National Forum on Health (NFOH). Canada Health Action: building on the legacy. Ottawa: Health Canada, 1997

    Google Scholar 

  35. Woodhouse KW. The clinical perspective. Cardiology 1994; 85 Suppl. 1: 36–40

    Article  Google Scholar 

  36. Guidelines for the economic evaluation of pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997

  37. Godwin M, Chapman J, Mowat D, et al. Delisting of drugs in Ontario. Can Fam Physician 1996; 42: 1309–16

    PubMed  CAS  Google Scholar 

  38. Smith DM, McKercher PL. The elemination of selected drug products from the Michigan Medicaid Formulary: a case study. Hosp Formul 1984; 14: 366–72

    Google Scholar 

  39. Zurwitz JH, McLaughlin TJ, Fish LS. The effect of an Rx-to- OTC switch on medication prescribing patterns and utilisation of physician services: the case of vaginal antifungal products. Health Serv Res 1995; 30(5): 672–83

    Google Scholar 

  40. Anderson MC, Bolton C, Gordon J, et al. Competition and the pharmaceutical value chain: competitive issues in the overthe- counter and generic drug segments of the Canadian pharmaceutical industry. Queens Health Policy. Kingston: Queens University, 1995

    Google Scholar 

  41. Harrison P. Rx to OTC: how will the switches impact on pharmacies? Pharm Pract 1994; 10(4): 45–9

    Google Scholar 

  42. Canadian Pharmaceutical Association (CPhA). Provincial Drug Benefit Programs. 16th ed. Ottawa, 1996

    Google Scholar 

  43. Jang R. Medicaid formularies: a critical review of the literature. J Pharm Market Manage 1988; 2(3): 39–61

    CAS  Google Scholar 

  44. Angus DE, Auer L, Cloutier JE, et al. Sustainable health care for Canada. Ottawa: Queens University of Ottawa Economic Projects, 1995

    Google Scholar 

  45. Angus DE. Review of significant health care commissions and task forces since 1983-84. Ottawa: Canadian Hospital Association, 1991

    Google Scholar 

  46. Canadian College of Health Service Executive. tExternal Environmental Analysis and Health Reform Update. Special Report: Ottawa, 1994

    Google Scholar 

  47. Strand LM Cipolle RJ, Morley PC. Pharmaceutical care: an introduction. The Upjohn Company of Canada. Don Mills, circa 1991

  48. Lipton HH, Bero LA, Bird JA, et al. The impact of clinical pharmacists consultations on physicians geriatric drug prescribing. Med Care 1992; 30: 646–55

    Article  PubMed  CAS  Google Scholar 

  49. Anderson GM, Lexchin J. Strategies for improving prescribing practice. Can Med Assoc J 1996; 154(7): 1013–7

    CAS  Google Scholar 

  50. Redwood H. New drugs in the world market: incentives and impediments to innovation. Am Enterprise 1993; 4(4): 72–80

    Google Scholar 

  51. Coambs RB, Jensen P, Her MH, et al. Review of the literature on the prevalence, consequences and health costs of non-compliance and inappropriate use of prescription medication in Canada. Prepared for Pharmaceutical Manufacturers Association of Canada. Toronto: University of Toronto Press, 1

    Google Scholar 

  52. Hovancsak CF, Yates WN, Schafermeyer KW. A study of the effectiveness of the Kansas drug utilisation review program. Kansas Drug Utilisation Rev Newsl 1984; 6(11): 1–4

    Google Scholar 

  53. Groves R. Therapeutic drug-use review for the Florida Medicaid program. Am J Hosp Pharm 1985; 42: 316–9

    PubMed  CAS  Google Scholar 

  54. Pursel MB. Evaluation of the DUR program for the Iowa medical assistance program. Iowa Pharmacist. Des Moines, Iowa: Iowa Pharmacists Association, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MHA Programme, Faculty of Administration, University of Ottawa, 136 Jean-Jacques Lussier, C.P. 450, Succ A, Ottawa, Ontario, K1N 6N5, Canada

    Douglas E. Angus & Heather M. Karpetz

Authors
  1. Douglas E. Angus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather M. Karpetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Angus, D.E., Karpetz, H.M. Pharmaceutical Policies in Canada. Pharmacoeconomics 14 (Suppl 1), 81–96 (1998). https://doi.org/10.2165/00019053-199814001-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814001-00011

Keywords

Search

Navigation